Roiver Score™ for
KPTIKaryopharm Therapeutics Inc.
Based on fundamentals through 12/31/2025.
As of December 31, 2025, Karyopharm Therapeutics Inc. (KPTI) scores 25/100 (Mixed) on the Roiver Score — a transparent quality composite. Its strongest area is profitability; its weakest is stability. The score measures business quality, not timing — it's a signal, not a recommendation.
No black box
Roiver Score is a transparent 0–100 quality composite. Five components, each 0–20: profitability, capital structure, cash quality, valuation, and stability. Inspired by Piotroski's F-Score, Altman's Z-Score, and the Buffett/Munger framework on quality compounders at fair prices. Read the full methodology →
Frequently asked about KPTI
What is KPTI's Roiver Score?
Karyopharm Therapeutics Inc. scores 25 out of 100 (Mixed) as of December 31, 2025, based on fundamentals.
How is the Roiver Score for KPTI calculated?
It sums five 0–20 components — profitability, capital structure, cash quality, valuation, and stability — into a transparent 0–100 composite. The full methodology is published.
Is KPTI a good quality stock?
On quality, KPTI rates "Mixed" (25/100). Its strongest driver is profitability and its weakest is stability. Quality is one input to a decision, not a buy/sell call.
Embed on your site
Drop this iframe into a Substack, blog post, or notion page. Updates automatically as fundamentals change.
<iframe src="https://roiver.com/embed/score/KPTI" width="640" height="280" frameborder="0" style="border:0;border-radius:16px;overflow:hidden" loading="lazy"></iframe>
Get KPTI's Score in your inbox
A free weekly digest of quality scores and what changed. No account needed.
Educational use only. Roiver Score is a quality signal, not a recommendation.